---
title: "Apimeds Pharmaceuticals US FY 2025: Revenue $0 Net loss $6M, EPS $(0.55) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285061804.md"
description: "Apimeds Pharmaceuticals US, Inc. reported a net loss of $6M for FY 2025 on $0 revenue, compared to a $1.4M loss in FY 2024. The diluted EPS was $(0.55) based on 10.88M shares. The company completed its NYSE IPO on May 12, 2025, raising approximately $11.6M. It also acquired MindWave, expanding into digital assets. R&D spending reached $1.6M, with plans for further funding and clinical advancements through 2026."
datetime: "2026-05-04T11:05:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285061804.md)
  - [en](https://longbridge.com/en/news/285061804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285061804.md)
---

# Apimeds Pharmaceuticals US FY 2025: Revenue $0 Net loss $6M, EPS $(0.55) — 10-K Summary

Apimeds Pharmaceuticals US, Inc. reported a net loss of $6M for fiscal 2025 on revenue of $0 compared with a net loss of $1.4M and no revenue in fiscal 2024; diluted loss per share was $(0.55) in 2025 based on 10.88M weighted‑average shares — 10-K Summary.

**Financial Highlights**

-   Revenue was $0 for FY 2025 and FY 2024 (no revenue from biopharmaceutical or MindWave operations).
-   Net income: Net loss of $6.0M for FY 2025, compared with net loss of $1.4M for FY 2024.
-   Diluted earnings per share: $(0.55) per share for FY 2025 (basic and diluted), based on 10.88M weighted‑average shares.

**Business Highlights**

-   IPO and public listing: Completed NYSE IPO on May 12, 2025, providing public market access and approximately $11.6M in net proceeds to support operations.
-   Strategic merger expansion: Acquired MindWave on Dec. 1, 2025, creating a dual‑segment company that adds digital asset operations and blockchain ecosystem management.
-   Operational scale‑up: Ramped biopharma activities in 2025, with $1.6M in R&D spend, CRO engagements, and $2M in prepaid clinical services for Apitox trials.
-   Digital asset monetization & activity: Realized and unrealized gains from NILA token sales and BTC holdings bolstered non‑operating income and provided additional liquidity options.
-   Near‑term funding and clinical plan: Management intends to draw remaining PIPE tranches, continue token sales, and advance Apitox manufacturing and clinical work through 2026.

Original SEC Filing: Apimeds Pharmaceuticals US, Inc. \[ APUS \] - 10-K - May. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [APUS.US](https://longbridge.com/en/quote/APUS.US.md)

## Related News & Research

- [Apimeds Secures Forbearance to Support Listing Remediation](https://longbridge.com/en/news/285062952.md)
- [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md)
- [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md)
- [PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely](https://longbridge.com/en/news/286912396.md)
- [Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA | HNSA Stock News](https://longbridge.com/en/news/286864132.md)